REYVOW FDA approval date

The FDA approved REYVOW on 11 Oct 2019.

FDA approval date
11 Oct 2019

Drug identity has not yet been verified against registry records

Also recorded as LASMIDITAN SUCCINATE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2019-10-11DayREYVOWFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA211280", "applicant_as_listed_by_fda": "ELI LILLY AND CO", "brand_names": ["REYVOW"], "active_ingredients": ["LASMIDITAN SUCCINATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20191011", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026